MicroRNA expression in BRAF-mutated and wild-type metastatic melanoma and its correlation with response duration to BRAF inhibitors

Bibliography

• Eggermont AM, Spatz A, Robert C. Cutaneous melanoma. Lancet 2014;383(9919):816-27
   PubMed Web of Science ®Google Scholar
• Bertolotto C. Melanoma: from melanocyte to genetic alterations and clinical options. Scientifica (Cairo) 2013;2013:635203
   PubMedGoogle Scholar
• Bello DM, Ariyan CE, Carvajal RD. Melanoma mutagenesis and aberrant cell signaling. Cancer Contr 2013;20(4):261-81
   Google Scholar
• Guida M, Pisconti S, Colucci G. Metastatic melanoma: the new era of targeted therapy. Expert Opin Ther Targets 2012;16(Suppl 2):S61-70
   Google Scholar
• Voskoboynik M, Arkenau HT. Improving patient selection for phase I oncology trials. J Clin Oncol 2014;32(28):3198-9
   Google Scholar
• Tentori L, Lacal PM, Graziani G. Challenging resistance mechanisms to therapies for metastatic melanoma. Trends Pharmacol Sci 2013;34(12):656-66
   PubMed Web of Science ®Google Scholar
• Flaherty KT, Infante JR, Daud A, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012;367(18):1694-703
   PubMed Web of Science ®Google Scholar
• Ackerman A, Klein O, McDermott DF, et al. Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors. Cancer 2014;120(11):1695-701
   PubMed Web of Science ®Google Scholar
• Van Allen EM, Wagle N, Sucker A, et al. The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. Cancer Discov 2014;4(1):94-109
   PubMed Web of Science ®Google Scholar
• Rizos H, Menzies AM, Pupo GM, et al. BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact. Clin Cancer Res 2014;20(7):1965-77
   PubMed Web of Science ®Google Scholar
• van den Hurk K, Niessen HE, Veeck J, et al. Genetics and epigenetics of cutaneous malignant melanoma: a concert out of tune. Biochim Biophys Acta 2012;1826(1):89-102
   PubMed Web of Science ®Google Scholar
• Lee JJ, Murphy GF, Lian CG. Melanoma epigenetics: novel mechanisms, markers, and medicines. Lab Invest 2014;94(8):822-38
   PubMed Web of Science ®Google Scholar
• Sarkar D, Leung EY, Baguley BC, et al. Epigenetic regulation in human melanoma: Past and future. Epigenetics 2015;10(2):103-21
   PubMed Web of Science ®Google Scholar
• Luo C, Weber CE, Osen W, et al. The role of microRNAs in melanoma. Eur J Cell Biol 2014;93(1-2):11-22
   Google Scholar
• Sun V, Zhou WB, Majid S, et al. MicroRNA-mediated regulation of melanoma. Br J Dermatol 2014;171(2):234-41
   PubMed Web of Science ®Google Scholar
• Voller D, Ott C, Bosserhoff A. MicroRNAs in malignant melanoma. Clin Biochem 2013;46(10-11):909-17
   Google Scholar
• Greenberg E, Nemlich Y, Markel G. MicroRNAs in cancer: lessons from melanoma. Curr Pharm Des 2014;20(33):5246-59
   Google Scholar
• Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45(2):228-47
   PubMed Web of Science ®Google Scholar
• Dweep H, Sticht C, Pandey P, Gretz N. miRWalk–database: prediction of possible miRNA binding sites by “walking” the genes of three genomes. J Biomed Inform 2011;44(5):839-47
   PubMed Web of Science ®Google Scholar
• Cline MS, Smoot M, Cerami E, et al. Integration of biological networks and gene expression data using Cytoscape. Nat Protoc 2007;2(10):2366-82
   PubMed Web of Science ®Google Scholar
• Maere S, Heymans K, Kuiper M. BiNGO: a Cytoscape plugin to assess overrepresentation of gene ontology categories in biological networks. Bioinformatics 2005;21(16):3448-9
   PubMed Web of Science ®Google Scholar
• Ascierto PA, Simeone E, Giannarelli D, et al. Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use. J Transl Med 2012;10:107
   PubMed Web of Science ®Google Scholar
• Ackerman A, Klein O, McDermott DF, et al. Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors. Cancer 2014;120(11):1695-701
   PubMed Web of Science ®Google Scholar
• Caramuta S, Egyhazi S, Rodolfo M, et al. MicroRNA expression profiles associated with mutational status and survival in malignant melanoma. J Invest Dermatol 2010;130(8):2062-70
   PubMed Web of Science ®Google Scholar
• Wang H, Xu C, Kong X, et al. Trail resistance induces epithelial-mesenchymal transition and enhances invasiveness by suppressing PTEN via miR-221 in breast cancer. PLoS One 2014;9(6):e99067
   Google Scholar
• Zhao G, Cai C, Yang T, et al. MicroRNA-221 induces cell survival and cisplatin resistance through PI3K/Akt pathway in human osteosarcoma. PLoS One 2013;8(1):e53906
   PubMed Web of Science ®Google Scholar
• Calderaro J, Rebouissou S, de Koning L, et al. PI3K/AKT pathway activation in bladder carcinogenesis. Int J Cancer 2014;134(8):1776-84
   Google Scholar
• Luo C, Merz PR, Chen Y, et al. MiR-101 inhibits melanoma cell invasion and proliferation by targeting MITF and EZH2. Cancer Lett 2013;341(2):240-7
   PubMed Web of Science ®Google Scholar
• Li P, He QY, Luo CQ, Qian LY. Circulating miR-221 expression level and prognosis of cutaneous malignant melanoma. Med Sci Monit 2014;20:2472-7
   PubMed Web of Science ®Google Scholar
• Jiang L, Lv X, Li J, et al. The status of microRNA-21 expression and its clinical significance in human cutaneous malignant melanoma. Acta Histochem 2012;114(6):582-8
   PubMed Web of Science ®Google Scholar
• Chen J, Feilotter HE, Pare GC, et al. MicroRNA-193b represses cell proliferation and regulates cyclin D1 in melanoma. Am J Pathol 2010;176(5):2520-9
   PubMed Web of Science ®Google Scholar
• Chen J, Zhang X, Lentz C, et al. miR-193b Regulates Mcl-1 in Melanoma. Am J Pathol 2011;179(5):2162-8
   PubMed Web of Science ®Google Scholar
• Lenarduzzi M, Hui AB, Alajez NM, et al. MicroRNA-193b enhances tumor progression via down regulation of neurofibromin 1. PLoS One 2013;8(1):e53765
   Google Scholar
• Hu H, Li S, Liu J, Ni B. MicroRNA-193b modulates proliferation, migration, and invasion of non-small cell lung cancer cells. Acta Biochim Biophys Sin (Shanghai) 2012;44(5):424-30
   Google Scholar
• Li J, Kong F, Wu K, et al. miR-193b directly targets STMN1 and uPA genes and suppresses tumor growth and metastasis in pancreatic cancer. Mol Med Rep 2014;10(5):2613-20
   PubMed Web of Science ®Google Scholar
• Tahiri A, Leivonen SK, Luders T, et al. Deregulation of cancer-related miRNAs is a common event in both benign and malignant human breast tumors. Carcinogenesis 2014;35(1):76-85
   PubMed Web of Science ®Google Scholar
• Feinberg-Gorenshtein G, Guedj A, Shichrur K, et al. MiR-192 directly binds and regulates Dicer1 expression in neuroblastoma. PLoS One 2013;8(11):e78713
   Google Scholar
• Xu YJ, Fan Y. MiR-215/192 participates in gastric cancer progression. Clin Transl Oncol 2015;17(1):34-40
   Google Scholar
• Odenthal M, Bollschweiler E, Grimminger PP, et al. MicroRNA profiling in locally advanced esophageal cancer indicates a high potential of miR-192 in prediction of multimodality therapy response. Int J Cancer 2013;133(10):2454-63
   PubMed Web of Science ®Google Scholar
• Liu X, Yu H, Cai H, Wang Y. The expression and clinical significance of miR-132 in gastric cancer patients. Diagn Pathol 2014;9:57
   Google Scholar
• Liu Q, Liao F, Wu H, et al. Upregulation of miR-132 expression in glioma and its clinical significance. Tumour Biol 2014;35(12):12299-304
   Google Scholar
• Zheng YB, Luo HP, Shi Q, et al. miR-132 inhibits colorectal cancer invasion and metastasis via directly targeting ZEB2. World J Gastroenterol 2014;20(21):6515-22
   PubMed Web of Science ®Google Scholar